Background and Purpose-Hepatocyte growth factor (HGF) is positively associated with ischemic and hemorrhagic stroke risk factors. However, understanding the relation between HGF and stroke is in its infancy. Therefore, we sought to examine the association of circulating HGF with incident stroke using data from the MESA (Multi-Ethnic Study of Atherosclerosis). We hypothesized that circulating HGF would be positively associated with an increased risk of stroke. Methods-Participants aged 45 to 84 years (n=6711) had HGF measured between 2000 and 2002 and were followed for incident stroke through 2013 (n=233). Cox proportional hazards regression was used to calculate hazard ratios and 95% confidence intervals for incident stroke. A secondary analysis stratified results by adjudicated stroke type (n=183 ischemic; n=39 hemorrhagic; n=11 other). Results-After adjustment for potential confounding variables, risk of stroke was 17% higher with each standard deviation increase in HGF (hazard ratio, 1.17; 95% confidence interval, 1.03-1.34). This association was mainly driven by ischemic stroke and did not change on exclusion of cardioembolic strokes, although the number of excluded cases was small. The few hemorrhagic and other types of stroke were not associated with HGF. Conclusions-Circulating HGF was positively associated with the incidence of stroke in a diverse, population-based cohort of men and women from the United States. Our findings support the hypothesis that circulating HGF is a marker of endothelial damage and suggest that HGF may have utility as a prognostic marker of stroke risk. (Stroke. 2016;47:00-00.
T he protein hepatocyte growth factor (HGF) and its receptor c-Met are produced in response to tissue injury and are functional in tissue repair mechanisms. Their favorable effects in the heart and vasculature include anti-inflammatory, antifibrotic, and proangiogenic actions. 1 Because HGF is released in response to endothelial injury, higher levels of circulating HGF are associated with hypertension, diabetes mellitus, smoking, increased age, body mass index (BMI), and presence and severity of atherosclerotic disease in both the heart and the lower extremities. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Despite evidence of a relation of circulating HGF with ischemic and hemorrhagic stroke risk factors, understanding the connection between HGF and stroke is in its infancy. Although previous studies indicate a positive relation between circulating HGF and both ischemic stroke and prognostic factors for the development of stroke, they are limited in that they were conducted in select populations that may not generalize. [13] [14] [15] [16] In addition, only one of these studies measured HGF before stroke, which is important to establish temporality. Finally, the associations of HGF with hemorrhagic stroke and all strokes (hemorrhagic and ischemic combined) have not been reported.
Therefore, we sought to examine the relation between circulating HGF and incident stroke using data from a large, multiethnic, population-based prospective cohort study: the MESA (MultiEthnic Study of Atherosclerosis). We hypothesized that circulating HGF would be positively associated with an increased risk of incident stroke. As a secondary analysis, we explored whether there were differences in the association with HGF by stroke type.
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participants aged 45 to 84 years and free of clinically recognized cardiovascular disease from populations near 6 field centers in Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Angeles, CA; New York, NY; and St Paul, MN. Cardiovascular disease at baseline was defined as heart attack, angina, stroke, transient ischemic attack, heart failure, resuscitated cardiac arrest, or having undergone procedures related to cardiovascular disease. The study participants were non-Hispanic white Americans (38%), blacks (28%), Hispanic Americans (22%), and Chinese Americans (12%). In total, 6772 participants had serum HGF measured at baseline as part of an ancillary study (HL98077; MESA Adhesion Study). Of these 6772 participants, we excluded individuals from all analyses if they had an extreme value of HGF defined as 4 or more standard deviations beyond the mean (n=31) or had not been followed after baseline (n=30). Our final sample size for statistical analyses was 6711. The institutional review boards at participating centers approved MESA and its ancillary studies, and all participants gave written informed consent.
Baseline Measurements

Measurement of HGF
Venous blood was obtained from fasting participants. Serum separation was performed within 30 minutes of phlebotomy, and aliquots were subsequently stored at −70°C. Circulating levels of HGF protein were measured in serum using a quantitative sandwich enzyme-linked immunosorbent assay with the Quantikine Human HGF Immunoassay kit (R&D Systems, Minneapolis, MN). This method was validated by R&D Systems, as specified in the package insert, and verified by the University of Minnesota laboratory that measured HGF for this study. The lower limit of detection was 40 pg/mL. The interassay laboratory coefficients of variation were 12.0%, 8.0%, and 7.4% at respective mean concentrations of 687, 2039, and 4080 pg/mL for lyophilized manufacturer's controls and 10.4% at a mean concentration of 688 pg/mL for an in-house pooled serum control.
Other Baseline Measurements
Sex, age, race/ethnicity, cigarette smoking status, and medication use were self-reported. In addition, participants were asked to bring all medications to the examination. BMI was calculated as weight over height squared (kg)/(m 2 ). Resting blood pressure was measured 3 times in the seated position using a Dinamap model PRO 100 automated oscillometric sphygmomanometer (Critikon, Tampa, FL). The average of the last 2 measurements was used in analyses. Participants were asked to fast for at least 8 hours before their visit. Serum glucose was assayed by a glucose oxidase method on the Vitros analyzer (Johnson & Johnson Clinical Diagnostics, Rochester, NY). Diabetes mellitus was defined as use of insulin or other diabetes mellitus medication, self-reported physician diagnosis, fasting glucose ≥126 mg/dL, or nonfasting glucose ≥200 mg/ dL. Total cholesterol was measured in EDTA plasma using a cholesterol oxidase method (Roche Diagnostics, Indianapolis, IN) on a Roche COBAS FARA centrifugal analyzer. After precipitation of non-high-density lipoprotein cholesterol with magnesium/dextran, high-density lipoprotein cholesterol was also measured in EDTA plasma using the cholesterol oxidase method (Roche Diagnostics). Using the Friedewald formula, low-density lipoprotein cholesterol was calculated in plasma samples with a triglyceride value <400 mg/ dL. Triglyceride was measured in EDTA plasma using Triglyceride Glycerol Blanked reagent (Roche Diagnostics) on a Roche COBAS FARA centrifugal analyzer.
Stroke Ascertainment
Forms for ascertaining events are available on the MESA Web site (http://www.mesa-nhlbi.org). A standard adjudication protocol was used to classify events, as previously reported. 18 In brief, a telephone interviewer contacted each participant at intervals of 9 to 12 months to inquire about all interim hospital admissions, cardiovascular outpatient diagnoses and procedures, and deaths. To verify self-reported diagnoses, copies of death certificates and medical records were requested. Hospital medical records were obtained on 99% of hospitalized cardiovascular events, and some information was obtained on 97% of outpatient diagnostic encounters.
Two vascular neurologists independently reviewed and classified stroke events and assigned incidence dates. If a disagreement between reviewers persisted after review and adjudication, the case was discussed and a consensus reached. Reviewers classified stroke as present if a focal neurological deficit lasted at least 24 hours or until death or, for deficits lasting <24 hours, a clinically relevant lesion was evident on brain imaging with computed tomography or magnetic resonance imaging, and no nonvascular cause was identified. Patients with focal neurological deficits from a nonvascular cause were adjudicated as not a stroke. Strokes were classified on the basis of neuroimaging or other tests into 3 types: ischemic, hemorrhagic, or other. Other strokes included those with incomplete evaluations and with rare, specific causes of stroke. Using strict criteria that required a complete stroke evaluation, ischemic strokes were subtyped into large artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined cause, or stroke of undetermined cause. Hemorrhagic strokes were subtyped into intraparenchymal hemorrhage, subarachnoid hemorrhage, or other hemorrhage.
Incident stroke was defined as the first occurrence of an adjudicated stroke from baseline through the end of follow-up on December 31, 2013. Follow-up for all analyses was calculated as the time elapsed from the baseline examination to whichever came first: first stroke event (regardless of type), loss to follow-up, death, or December 31, 2013.
Statistical Analyses
Unless stated otherwise, analyses were performed using SAS statistical software, version 9.4. A P value of <0.05 on a 2-tailed test was considered statistically significant. Baseline participant characteristics are presented by HGF tertile and compared using the χ 2 test for categorical variables and the analysis of variance F test for continuous variables. Stroke incidence rates by HGF tertile were calculated using Poisson regression. A Kaplan-Meier plot was produced using R statistical software. We used Cox regression with restricted cubic splines to visually check the linearity of the relation between HGF and stroke, modeling HGF as a continuous variable, by graphing the natural log of the hazard ratio (HR) on the y axis (data not shown). 19 Because we found no evidence of nonlinearity, we modeled HGF as a continuous measure. Cox regression was used to calculate HRs and 95% confidence intervals (CIs) for incident stroke per 1SD (259 pg/ mL) increase in HGF. Model 1 adjusted for age, race/ethnicity, and sex. Model 2 was adjusted for variables in model 1 plus baseline values of BMI, smoking status, diabetes mellitus, systolic blood pressure, antihypertensive medication use, high-density lipoprotein cholesterol, total cholesterol, low-density lipoprotein cholesterol, triglycerides, lipid-lowering medication use, and field center site. Further inclusion of variables known to be risk factors for stroke or associated with circulating HGF-cancer, estimated glomerular filtration rate, diastolic blood pressure, level of education, physical activity, interleukin-6, d-dimer, C-reactive protein, and left ventricular hypertrophy-did not appreciably change point estimates and thus were not included in our final model. By including cross-product terms in models, we tested for interactions with age, sex, race/ethnicity, and hypertension status. We verified the proportional hazards assumption through inspection of ln(-ln) survival curves by HGF tertile and evaluation of the Schoenfeld residuals. As a secondary analysis, we used Cox regression to calculate HRs by stroke type. We censored person-years at the time of the first stroke, regardless of type, for this secondary analysis. As a sensitivity analysis, we restricted follow-up time to 3 years. As an additional sensitivity analysis, we modeled HGF as a time-varying covariate, using baseline and, when available, visit 2 measurements of HGF. MESA measured HGF in everyone at baseline and in a random sample of 2418 people at visit 2. If a participant did not have HGF measured at visit 2, the measurement from visit 1 was carried forward. 
Results
The mean age of MESA participants at baseline was 62 years, and ≈50% were women. Table II in the online-only Data Supplement). During a maximum of 13.5 years of follow-up, the proportion that survived free of stroke was significantly different by HGF tertile (log-rank test, P≤0.0001; Figure) .
Circulating HGF was a risk marker for incident stroke (Table 2) . After adjustment for sex, race/ethnicity, and age, risk of stroke was 30% higher with each standard deviation increase in HGF. Adjustment for other stroke risk factors attenuated the association between HGF and stroke, but it remained statistically significant (HR, 1.17; 95% CI, 1.03-1.34). This association was modestly stronger if we restricted follow-up time to 3 years (HR, 1.35; 95% CI, 1.05-1.72), but did not appreciably change in an analysis that treated HGF as a time-varying (Table 2 ). In fully adjusted models, risk of ischemic stroke was 21% higher with each standard deviation increase in HGF and did not change on exclusion of cardioembolic strokes, although the number of excluded cases was small. Hemorrhagic strokes and other strokes were not associated with HGF, but their numbers were also small.
Discussion
In this multiethnic population-based cohort, we found that participants with higher levels of circulating HGF at baseline had a greater risk of incident stroke, independent of other risk factors. This association was mainly driven by ischemic stroke and did not change on exclusion of cardioembolic strokes, although the number of excluded cases was small. We were underpowered to detect all but a strong association in hemorrhagic and other types of stroke. Finally, we report a strong positive relation between circulating HGF and many stroke risk factors.
Our study corroborates findings from previous studies, which reported a positive relation between circulating HGF and ischemic stroke 15, 16 and between circulating HGF and prognostic factors for the development of stroke. 13, 14 However, only one of these studies measured HGF before stroke, which is important to establish temporality. It is found, in the predominantly white cohort of postmenopausal women that comprises the Women's Health Initiative (WHI), that risk of incident ischemic stroke was 40% higher for women in the highest quartile of plasma HGF versus the lowest in fully adjusted models. 1 Our study expands on work from previous studies by using a diverse population-based cohort, using a prospective design, and reporting the relation of HGF with all strokes (ischemic and hemorrhagic combined) and hemorrhagic stroke.
HGF plays a key role in tissue repair by aiding in the protection and regeneration of vascular endothelial cells. 1, [20] [21] [22] [23] Therefore, it should come as no surprise that both the present study and others have reported a strong positive relation between circulating HGF and stroke risk factors that are associated with endothelial damage and dysfunction, including hypertension, diabetes mellitus, smoking, age, and BMI. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Importantly, HGF and stroke were still related after accounting for stroke risk factors. This observation lends credence to the hypothesis that HGF is not simply a surrogate for stroke risk factors but rather a marker of endothelial damage. 23 Biological mechanisms of an HGF stroke relation may differ by stroke type. To explore this possibility, as a secondary analysis, we excluded cardioembolic stroke, which is typically related to atrial fibrillation, from the definition of ischemic stroke, leaving only ischemic strokes predominantly related to atherosclerotic factors. We found that the relation between HGF and ischemic stroke did not change on exclusion of cardioembolic strokes. However, the number of excluded cases may have been too small to affect the results. In accordance, the WHI investigators reported that the HGF-stroke association did not vary by subtype of ischemic stroke; however, the data were not shown, thus leaving unresolved if they had an adequate number of strokes to produce reliable estimates. 16 Study limitations warrant discussion. The limited number of incident stroke events in this study precluded our ability to evaluate the HGF-stroke relation within subgroups of interest.
In particular, future research should explore the HGF-stroke relation by race/ethnicity because race/ethnicity-specific genetic regulation of HGF levels justifies exploration of heterogeneity of phenotypes. 24 Also, although we did not detect an association between HGF and hemorrhagic stroke, we were underpowered with only 39 events to date. Finally, HGF was measured in the total cohort only once at baseline, and stroke events could have occurred more than a decade after this measurement. HGF levels are relatively stable over 3 years, indicating that a single baseline measurement of circulating HGF is reasonable to use as a marker of an individual's exposure to this protein during this time period. 25 Therefore, as a sensitivity analysis, we restricted follow-up to 3 years so that strokes were closer to the baseline HGF measurement. The association between HGF and risk of stroke was modestly stronger. As an additional sensitivity analysis, we modeled HGF as a time-varying covariate using baseline and, when available, visit 2 measurements of HGF. The advantage of this approach is that it more accurately represents the long-term level of HGF by accommodating changes during time. The association between HGF and risk of stroke did not appreciably change in this analysis. Thus, the timing and number of HGF measurements seem unlikely to drastically change the relation of HGF and stroke risk, but this issue deserves further attention. Future research could examine the association between serial HGF measurements and stroke risk. Strengths of this study include the prospective design; the large, population-based multiethnic sample with a wide geographic distribution in the United States; robust stroke adjudication; and highly standardized assessment of a broad array of stroke risk factors.
In conclusion, circulating HGF was positively associated with the incidence of stroke in a diverse, population-based cohort of men and women from the United States. This association was mainly driven by ischemic stroke because there were few hemorrhagic stroke events during follow-up. Our findings support the hypothesis that circulating HGF is a marker of endothelial damage and suggest that HGF may have utility as a prognostic marker of stroke risk. 
